195 related articles for article (PubMed ID: 31255482)
1. Hyperarousal in insomnia: pre-sleep and diurnal cortisol levels in response to chronic zolpidem treatment.
Roehrs T; Roth T
Sleep Med; 2019 Sep; 61():52-56. PubMed ID: 31255482
[TBL] [Abstract][Full Text] [Related]
2. Hyperarousal in insomnia and hypnotic dose escalation.
Roehrs TA; Roth T
Sleep Med; 2016 Jul; 23():16-20. PubMed ID: 27692272
[TBL] [Abstract][Full Text] [Related]
3. MSLT in primary insomnia: stability and relation to nocturnal sleep.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
Sleep; 2011 Dec; 34(12):1647-52. PubMed ID: 22131601
[TBL] [Abstract][Full Text] [Related]
4. Gender Differences in the Efficacy and Safety of Chronic Nightly Zolpidem.
Roehrs TA; Roth T
J Clin Sleep Med; 2016 Mar; 12(3):319-25. PubMed ID: 26446253
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.
Randall S; Roehrs TA; Roth T
Sleep; 2012 Nov; 35(11):1551-7. PubMed ID: 23115404
[TBL] [Abstract][Full Text] [Related]
7. Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
Sleep; 2011 Feb; 34(2):207-12. PubMed ID: 21286241
[TBL] [Abstract][Full Text] [Related]
8. Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.
Roehrs TA; Randall S; Harris E; Maan R; Roth T
J Psychopharmacol; 2012 Aug; 26(8):1088-95. PubMed ID: 22004689
[TBL] [Abstract][Full Text] [Related]
9. Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial.
McCall WV; Benca RM; Rosenquist PB; Youssef NA; McCloud L; Newman JC; Case D; Rumble ME; Szabo ST; Phillips M; Krystal AD
Am J Psychiatry; 2019 Nov; 176(11):957-965. PubMed ID: 31537089
[TBL] [Abstract][Full Text] [Related]
10. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
11. Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial.
Sharma MK; Kainth S; Kumar S; Bhardwaj A; Agarwal HK; Maiwall R; Jamwal KD; Shasthry SM; Jindal A; Choudhary A; Anand L; Dhamija RM; Kumar G; Sharma BC; Sarin SK
Clin Mol Hepatol; 2019 Jun; 25(2):199-209. PubMed ID: 30856689
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial.
Morin CM; Edinger JD; Beaulieu-Bonneau S; Ivers H; Krystal AD; Guay B; Bélanger L; Cartwright A; Simmons B; Lamy M; Busby M
JAMA Psychiatry; 2020 Nov; 77(11):1107-1115. PubMed ID: 32639561
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
Roth T; Soubrane C; Titeux L; Walsh JK;
Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
[TBL] [Abstract][Full Text] [Related]
14. Doxepin is more effective than zolpidem in improving executive function in patients with insomnia disorder.
Yu Z; Han L; Yan P; Liu W; Ren L; Xu Y; Yang L; Ma L; Liu Y; Wang S
Sleep Breath; 2024 May; 28(2):929-934. PubMed ID: 38123719
[TBL] [Abstract][Full Text] [Related]
15. Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.
Castro LS; Otuyama LJ; Fumo-Dos-Santos C; Tufik S; Poyares D
Braz J Psychiatry; 2020 Apr; 42(2):175-184. PubMed ID: 31859791
[TBL] [Abstract][Full Text] [Related]
16. How representative are insomnia clinical trials?
Roehrs T; Verster JC; Koshorek G; Withrow D; Roth T
Sleep Med; 2018 Nov; 51():118-123. PubMed ID: 30144651
[TBL] [Abstract][Full Text] [Related]
17. Assessing a hyperarousal hypothesis of insomnia in adults with autism spectrum disorder.
Baker EK; Richdale AL; Hazi A; Prendergast LA
Autism Res; 2019 Jun; 12(6):897-910. PubMed ID: 30896090
[TBL] [Abstract][Full Text] [Related]
18. Eight weeks of non-nightly use of zolpidem for primary insomnia.
Walsh JK; Roth T; Randazzo A; Erman M; Jamieson A; Scharf M; Schweitzer PK; Ware JC
Sleep; 2000 Dec; 23(8):1087-96. PubMed ID: 11145323
[TBL] [Abstract][Full Text] [Related]
19. Recurrent short sleep, chronic insomnia symptoms and salivary cortisol: A 10-year follow-up in the Whitehall II study.
Abell JG; Shipley MJ; Ferrie JE; Kivimäki M; Kumari M
Psychoneuroendocrinology; 2016 Jun; 68():91-9. PubMed ID: 26963375
[TBL] [Abstract][Full Text] [Related]
20. Zolpidem overutilisation among Korean patients with insomnia.
Kim H; Park S; Kim J; Je NK
J Sleep Res; 2020 Aug; 29(4):e13071. PubMed ID: 32406572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
